SAN FRANCISCO, Dec. 26, 2024 — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company focused on oligonucleotide therapies for a functional cure for chronic hepatitis B (CHB), today announced securing USD 73 million in Series B funding.
Led by HanKang Capital, the round included participation from Sherpa Capital, CDH Investments, a strategic investor, and existing investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital. This follows the company’s Series A round in July, showcasing investor confidence in its platform and strategy.
Funds will support continued Phase 2 development of AHB-137, AusperBio’s lead therapy, including clinical studies in China and globally, and commercial-scale manufacturing. The funding will also expand the company’s therapeutic pipeline and operations.
Dr. Guofeng Cheng, AusperBio’s co-founder and CEO, commented, “ This funding reflects our investors’ trust and supports our progress toward a functional cure for CHB patients. ”
Dr. Chris Yang, co-founder and CSO, added, “AHB-137’s presentation at the recent AASLD conference generated significant interest. The positive clinical data validates our Med-Oligo
platform, furthering our development of oligonucleotide therapies for CHB and other chronic diseases.”
AusperBio is dedicated to patient-focused innovation to address the global CHB burden and transform its treatment.
About AHB-137
AHB-137, a novel unconjugated antisense oligonucleotide (ASO) based on AusperBio’s Med-Oligo ASO technology, is designed for a functional cure of chronic hepatitis B. Its preclinical and Phase 1 clinical data were presented at the 2023 and 2024 EASL conferences, respectively. Interim Phase 2a data was presented at the 2024 AASLD. This dual-mechanism ASO has completed its global Phase 1b trial and is in multiple Phase 2 trials in China, progressing toward an HBV cure.
About AusperBio.
AusperBio, a clinical-stage biopharmaceutical company operating in the USA and China, focuses on oligonucleotide and targeted delivery technologies for therapies, initially targeting chronic hepatitis B. The company’s proprietary Med-Oligo ASO platform enhances ASO therapeutics. Combined with targeted delivery, the Med-Oligo platform enables ASO treatment of various diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
For further information, please contact:
Media Contact
Email:
Investor Relations Contact:
Tel: 650-888-1756 (US)
Email:
SOURCE AusperBio Therapeutics Inc.
“`